Advertisement

Prostaglandin Derivatives and Platelet-specific Proteins During Transluminal Coronary Angioplasty

  • K. Silberbauer
  • H. Sinzinger
  • G. Kober
Conference paper

Abstract

There is much speculation about the role of prostaglandins and thromboxanes in ischemic heart disease. These endogenous compounds are potent modulators of vascular smooth muscle tone and platelet aggregability. During platelet activation platelets generate a potent vasoconstrictor, thromboxane A2 (TXA2), whereas prostaglandin I2 (PGI2), produced by the vessel wall, is a potent vasodilator and inhibits platelet aggregation [5]. Both PGI2 and TXA2 are unstable and spontaneously convert to the inactive metabolites 6-Oxo-prostaglandin F1 α (6-Oxo-PGF1 α;) and thromboxane B2 (TXB2), respectively [2, 7]. In addition, the measurement of plasma concentrations of β-thromboglobulin (βTG), a specific protein, which is extruded from well-defined platelet granules into the surrounding medium, might reflect in vivo platelet activation [4].

Keywords

Platelet Activation Coronary Sinus Coronary Circulation Smooth Muscle Tone Coronary Sinus Blood 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dawes J, Smith RC, Pepper DS (1978) The release, distribution and clearance of human β-thromboglobulin and platelet factor. 4. Thromb Res 12:851–859PubMedCrossRefGoogle Scholar
  2. 2.
    Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994–2998PubMedCrossRefGoogle Scholar
  3. 3.
    Leithner C, Sinzinger H, Stummvoll HK, Klein K, Silberbauer K, Peskar BA (1980) Enhanced 6-oxo-PGF1 α levels in plasma during hemodialysis. Prostaglandins Med 5:425–427PubMedCrossRefGoogle Scholar
  4. 4.
    Ludlam CA, Bolton AE, Moore S, Cash JD (1975) New rapid method for diagnosis of deep vein thrombosis. Lancet II:259–260CrossRefGoogle Scholar
  5. 5.
    Moncada S, Vane JR (1979) Pharmacology and endogenous role’s of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293–331Google Scholar
  6. 6.
    Oates JA, Roberts LJ, Sweetnam BJ, Maas RL, Gerkens JF, Taber DF (1980) Metabolism of the prostaglandins and thromboxanes. In: Samuelson B, Ramwell PW, Paoletti R (eds) Advances in prostaglandin and thromboxane research. Raven Press, New York pp 35–41Google Scholar
  7. 7.
    Wong PV-K, Sun FF, McGiff JC (1978) Metabolism of prostacyclin in blood vessels. J Biol Chem 253:5555–5557PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • K. Silberbauer
    • 1
    • 2
  • H. Sinzinger
    • 1
    • 2
  • G. Kober
    • 1
    • 2
  1. 1.2nd Dept. of Internal MedicineUniversity of ViennaAustria
  2. 2.Dept. of CardiologyUniversity of Frankfurt a.M.Germany

Personalised recommendations